<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04214873</url>
  </required_header>
  <id_info>
    <org_study_id>Focus-PiQo4 POH-19-03</org_study_id>
    <nct_id>NCT04214873</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effectiveness of the PiQo4 System for Reduction of Infra-orbital Pigmentation</brief_title>
  <official_title>A Pilot Study to Evaluate the Effectiveness of the PiQo4 Picosecond Laser (PSL) System for Reduction of Infra-orbital Pigmentation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Focus Medical, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Focus Medical, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 10 healthy subjects at a single site, aged 18-65 years old and Fitzpatrick skin
      type I-IV with mild to moderate infra-orbital hyperpigmentation on the background of
      epidermal and/or dermal pigmentation that wish to improve their POH
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in POH severity</measure>
    <time_frame>3 month follow up</time_frame>
    <description>POH improvement of at least 1 point evaluated by the investigator at the 3-month follow up compared to baseline using the POH severity in comparison to surrounding skin scale where score of between 0 and 4 will be assigned (0-Normal (Skin color comparable to other facial skin areas); 1- Trace (Faint pigmentation of infraorbital fold (bilateral)); 2- Mild (Pigmentation more pronounced); 3- Moderate (Deep dark colour, all four lids involved): ; 4 - Marked (Grade 3 + pigmentation spreading beyond infraorbital fold)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aesthetic improvement</measure>
    <time_frame>3 month follow up</time_frame>
    <description>Aesthetic improvement evaluated by the investigator at the 3-month follow up compared to baseline using a 5-point improvement scale (GAIS) where a score of between 0 and 4 will be assigned (0-Worse (The appearance is worse than the original condition.); 1- No Change (The appearance is essentially the same as the original condition); 2- Improved (Obvious improvement in appearance from initial condition, but a touch-up or re-treatment is indicated.); 3- Much improved (Marked improvement in appearance from initial condition, but not completely optimal. A touch-up would slightly improve the result.); 4 - Very much improved (Optimal result)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>POH</condition>
  <arm_group>
    <arm_group_label>POH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of POH Using PiQo4 Laser System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PiQo4 Laser System</intervention_name>
    <description>PiQo4 Laser System for treatment of POH</description>
    <arm_group_label>POH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females or males

          2. Age 18-65

          3. Fitzpatrick skin types I-IV

          4. POH on the background of epidermal and/or dermal pigmentation

          5. POH severity - mild to moderate

          6. Able to read, understand and provide written Informed Consent.

          7. Able and willing to comply with the treatment/follow-up schedule and post treatment
             care

          8. Agreed to use the same facial skin care products during the clinical trial period
             (including the follow-up period)

          9. Agreed to the prohibition of the use of local/systemic corticosteroids or retinoids
             and other local/systemic lightening medications, and willing to abide by such
             instructions

         10. Agreed to the daily use of an over SPF 50 sunblock on their face during the clinical
             trial period (including the follow-up period), and willing to abide by such
             instructions

         11. Agreed to have their face photographed and willingness to allow Focus Medical (the
             study Sponsor) and Lumenis and the investigators to use de-identified photographs of
             the treated area for presentation and publication purposes

         12. Women of childrearing potential (not postmenopausal [no menstrual cycle for at least
             12 months], without an uterus and/or both ovaries, or has had a bilateral tubal
             ligation)

             *(In case of women of childbearing potential) Tested negative in the pregnancy test
             and agreed to use birth control measures during the clinical trial period including
             use of contraceptives (see list below) IUD, Double-Barrier Method, Vasectomized
             Partner, No Heterosexual Intercourse, etc

         13. Agreed not to undergo any other procedure on their face during their participation in
             the clinical trial

        Exclusion Criteria:

          1. Pregnant or breastfeeding

          2. Inability to comply with all study protocols and regulations

          3. Participation in a study of another device or drug

          4. Heavy smokers and/or drinkers (those who smoke 25 or more cigarettes a day and/or ⩾8
             drinks a week for women, and ⩾15 for men)

          5. Application of any energy device treatment to the infraorbital region within 3 months

          6. Application of any dermal filler to the infraorbital region within 6 months

          7. Facial resurfacing, deep chemical peels, or taking oral retinoids within 6 months

          8. Microdermabrasion (light or medium skin peel) treatment within 30 days

          9. Chemical peel, systemic steroids, non-ablative laser, light, or radiofrequency
             treatment within 3 months

         10. Use of topical lightening agents or retinoids within 14 days

         11. Any planned surgical intervention to the face for the duration of the trial

         12. Use of Latisse, Revitalash, or other lash enhancement stimulators as well as
             Bimatoprost in the previous 1 month

         13. Presence of open wounds, lesions, or scarring in the area

         14. Very thin skin (skin that tears, bruises, or breaks easily)

         15. Suffering from current or history of significant skin conditions in the treated area
             that could interfere with the evaluation (i.e. infection, dermatitis, or rash on their
             face) or requires the use of interfering topical or systemic therapy.

         16. Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning
             during the study.

         17. Having a history of diseases stimulated by heat, such as recurrent Herpes Simplex
             (HSV, HZO) in the treated area, unless treatment is conducted following a prophylactic
             regimen

         18. History of keloid scarring, hypertrophic scarring, or of abnormal wound healing.

         19. History of connective tissue diseases such as systemic lupus erythematosus or
             scleroderma

         20. History of post inflammatory pigmentary disorders, particularly a tendency for hyper-
             or hypo-pigmentation.

         21. History of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins
             or photodermatosis.

         22. Has used photosensitizing drugs (e.g., Declomycin, sulfa antibiotics, phenothiazines,
             etc.) within a timeframe where photosensitization from these drugs may still be
             present

         23. History of skin cancer

         24. Change of contraceptives dosing in the past 3 months

         25. Medical disorders such as thyroid or kidney diseases

         26. Significant concurrent illness or any disease state that in the opinion of the
             Investigator would interfere with the treatment or healing process

         27. As per the Investigator's discretion, any physical or mental condition which might
             make it unsafe for the subject to participate in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mitchel P Goldman, MD</last_name>
    <phone>858.657.1002</phone>
    <email>mgoldman@CLderm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leslie Aguilar</last_name>
    <phone>858.657.1004</phone>
    <phone_ext>120</phone_ext>
    <email>laguilar@clderm.com</email>
  </overall_contact_backup>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 25, 2019</study_first_submitted>
  <study_first_submitted_qc>December 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

